3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
3
Brain Neoplasms
2
Uveal Melanoma
1
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Noonan Syndrome 6
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma, Large-Cell, Anaplastic
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
fludarabine phosphate
2
avelumab
2
Magnetic Resonance Spectroscopy
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
veliparib
1
romidepsin
1
pasireotide
1
lutetium Lu 177 dotatate
1
fludarabine
1
entrectinib
1
alectinib
1
Temozolomide
1
Specimen Handling
1
Radiotherapy
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Lutetium-177
1
Lactones
1
Interleukin-13
1
Immunotherapy
1
FAPI-46
1
Drug Therapy
1
Depsipeptides
1
Capecitabine
1
Cabergoline
1
Biopsy
1
Biological Therapy
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
entrectinib
×
Dermatologic
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA